When was VitriVax founded?

VitriVax was founded in 2014 and raised its 1st funding round 6 years after it was founded.

Where is VitriVax located?

VitriVax is headquartered in Boulder, United States.

How many employees does VitriVax have?

As of Jun 30, 2026, the latest employee count at VitriVax is 54.

Is VitriVax a funded company?

VitriVax is a funded company, having raised a total of $46.7M across 7 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on May 22, 2020.

When was the latest funding round of VitriVax?

VitriVax's latest funding was a $***** Series B round on Oct 22, 2025, with participation from 2 investors.

Where does VitriVax rank among its competitors?

VitriVax ranks 1st amongst 3 active competitors, only 1 of which is funded. VitriVax, which secured $17.2M in Oct, 2025.

Who are the top competitors of VitriVax?

VitriVax's top competitors include Aahi, Proxi Biotech and Antelope Valley Bios. Among them, VitriVax secured the most recent funding round in October, 2025.

VitriVax - 2026 Company Profile, Team, Funding & Competitors

VitriVax is a series B company based in Boulder (United States), founded in 2014 by Theodore Randolph, Robert Garcea and Michael Artinger. It operates as a Developer of thermostable vaccines. VitriVax has raised $46.7M in funding from RA Capital Management and Adjuvant Capital. The company has 3 active competitors, including 1 that is funded. Its top competitors are Aahi, Proxi Biotech and Antelope Valley Bios.

Company Details

Developer of thermostable vaccines and vaccine formulations. It is using a proprietary platform technology named a single shot, prime + boost microparticle vaccine platform and developed at the University of Colorado. The platform uses nanoparticles of antigen and adjuvant in an amorphous disaccharide glass matrix, which improves the stability and solubility of the product. The company is using the platform to develop thermostable vaccines of Anthrax, Botulinum toxin, Ebola glycoprotein, and HPV16 L1 capsomere.

Key Metrics

Founded Year

2014

Location

Boulder, United States

Stage

Series B

Total Funding

$46.7M in 7 rounds

Latest Funding Round

Series B, Oct 22, 2025, $*****

Investors

RA Capital Management & 3 more

Ranked

1^st among 3 active competitors

Employee Count

54 as on Jun 30, 2026

Similar Companies

Aahi & 2 more

View VitriVax's full profile

VitriVax has raised a total funding of $46.7M over 7 rounds. Its first funding round was on May 22, 2020. Its latest funding round was a Series B round on Oct 22, 2025 for $*****. 2 investors participated in its latest round. VitriVax has 4 institutional investors.

Here is the list of recent funding rounds of VitriVax:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 22, 2025	1794366	Series B	8457981	1371547	3377867	3957021
Jun 30, 2025	4207729	Series B	7542628	2382140	6191586	9178867
Apr 28, 2025	8042677	Grant (prize money)	4476285	3551190	7893107	CEPI

Access funding benchmarks and valuations. Sign up today!

View details of VitriVax's funding rounds and investors

The founders of VitriVax are Theodore Randolph, Robert Garcea and Michael Artinger.

Here are the details of VitriVax's key team members:

Theodore Randolph: Co-Founder & CTO of VitriVax.
Contact Info: 1 email address
Robert Garcea: Co-Founder & CSO of VitriVax.
Contact Info: 1 email address
Michael Artinger: Co-Founder & CEO of VitriVax.

View details of VitriVax's Founder profiles and Board Members

VitriVax's employee count trend

VitriVax has 54 employees as of Jun 26. Here is VitriVax's employee count trend over the years:

Uncover VitriVax's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of VitriVax include Aahi, Proxi Biotech and Antelope Valley Bios. Here is the list of Top 10 competitors of VitriVax, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	VitriVax 2014, Boulder (United States), Series B	Developer of thermostable vaccines	$46.7M	RA Capital Management, Gates & 2 others	61/100
2nd	Aahi 1993, Seattle (United States), Funding Raised	Digital vaccine development tools and services	-	Gates, Military Health & 2 others	48/100
3rd	Proxi Biotech 2018, Copenhagen (Denmark), Funding Raised	Developer of vaccines to treat MDR bacterial infections	-	BioInnovation Institute, EIT Health	29/100
4th	Antelope Valley Bios 2015, Lincoln (United States), Acqui-Hired	Provider of vaccine discovery solutions	-	-	17/100